menu

BTKi Breakthroughs: Overcoming Treatment Resistance in CLL & MCL

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

BTKi Breakthroughs: Overcoming Treatment Resistance in CLL & MCL

4 chapters
Play All
1.00 credits
60 minutes
Chapter 1
ReachMD Healthcare Image
Restart
Resume
Choose a format
Take Post-TestSkip straight to the post-test if you have already participated in this activity
Media formats available:
1.00 credits
Completing the pre-test is required to access this content.
Completing the pre-survey is required to view this content.
Details
Presenters
Related
Comments
  • Overview

    Bruton’s tyrosine kinase inhibitors (BTKi) have transformed treatment for people with chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), and other B-cell malignancies. Still, many patients discontinue treatment because of adverse events and treatment resistance. As science moves forward in understanding why some patients do not respond well to treatment with BTKi, a new generation of BTKi with a different mechanism of action (MOA) is emerging as a possible therapeutic alternative.

    Now’s the time to learn about this promising new treatment path for CLL and MCL. In this activity, featuring four concise modules, an expert discusses the MOAs of covalent and non-covalent BTKi, current practices for using BTKi in treatment of CLL and MCL, the efficacy and safety data for novel BTKi, and the potential role of non-covalent BTKi in future treatment plans.

  • Disclosure of Conflicts of Interest

    Educational activities provided by Forefront Collaborative must demonstrate balance, independence, and scientific rigor. All those in a position to control the content of an activity must disclose all financial relationship(s) with ineligible companies.* For this educational activity, all conflicts of interest have been resolved through peer review and revisions to ensure independence, evidence base, fair balance, and absence of commercial bias. Disclosures appear below as they were at the launch of this activity. 

    *The Accreditation Council for Continuing Medical Education (ACCME) defines an ineligible company as any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. The ACCME does not consider providers of clinical service directly to patients to be ineligible companies—unless the provider of the clinical service is owned, or controlled by, an ACCME-defined ineligible company. 

    The following individuals have indicated that they have not had, in the past 24 months, a relevant financial relationship(s) with ineligible companies to disclose:

    • Planners (Forefront Collaborative): Leah Johnson; Marianna Shershneva, MD, PhD

    The following individuals have disclosed that they have had a financial relationship in the past 24 months that has been deemed relevant to this activity. All relevant financial relationships have been mitigated:

    Faculty: Julie E. Chang, MD

    • Research Funding: Celgene, Genentech
    • Consultant: MorphoSys 
    • Advisory Board: BeiGene, Genentech
  • Target Audience

    This activity is designed to meet the educational needs of hematology/oncology specialists, as well as nurse practitioners, physician assistants, pharmacists, and other members of a healthcare team who are involved in treatment of patients with CLL or MCL.

  • Learning Objectives

    Upon completion of this activity, learners should increase their ability to:

    1. Describe the MOAs of covalent and non-covalent BTKi used to treat patients with certain B-cell malignancies.
    2. Examine the most frequent causes of treatment failure with standard, covalent BTKi seen in patients with relapsed/refractory CLL or MCL.
    3. Assess the efficacy and safety of novel, non-covalent BTKi advancing through clinical trials among patients with CLL and MCL.
    4. Discuss the potential role for non-covalent BTKi in the treatment algorithm for patients with relapsed/refractory CLL or MCL.
  • Accreditation and Credit Designation Statements

    Accreditation Statement
    Forefront Collaborative is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    Credit Designation Statement
    Forefront Collaborative designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

  • Disclaimer

    The views and opinions expressed in this activity are those of the faculty and do not necessarily reflect the views or recommendations of Forefront Collaborative and Lilly.

    The content of this activity was independently peer reviewed by two reviewers. The reviewers of this activity have no relevant financial relationships to disclose.

    This continuing medical education activity will include references to unlabeled or unapproved uses of drugs.

  • Provider(s)/Educational Partner(s)

    This activity is provided by Forefront Collaborative.

  • Commercial Support

    This activity is supported by an educational grant from Lilly.

  • System Requirements

    Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments

Recommended
Details
Presenters
Related
Comments
  • Overview

    Bruton’s tyrosine kinase inhibitors (BTKi) have transformed treatment for people with chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), and other B-cell malignancies. Still, many patients discontinue treatment because of adverse events and treatment resistance. As science moves forward in understanding why some patients do not respond well to treatment with BTKi, a new generation of BTKi with a different mechanism of action (MOA) is emerging as a possible therapeutic alternative.

    Now’s the time to learn about this promising new treatment path for CLL and MCL. In this activity, featuring four concise modules, an expert discusses the MOAs of covalent and non-covalent BTKi, current practices for using BTKi in treatment of CLL and MCL, the efficacy and safety data for novel BTKi, and the potential role of non-covalent BTKi in future treatment plans.

  • Disclosure of Conflicts of Interest

    Educational activities provided by Forefront Collaborative must demonstrate balance, independence, and scientific rigor. All those in a position to control the content of an activity must disclose all financial relationship(s) with ineligible companies.* For this educational activity, all conflicts of interest have been resolved through peer review and revisions to ensure independence, evidence base, fair balance, and absence of commercial bias. Disclosures appear below as they were at the launch of this activity. 

    *The Accreditation Council for Continuing Medical Education (ACCME) defines an ineligible company as any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. The ACCME does not consider providers of clinical service directly to patients to be ineligible companies—unless the provider of the clinical service is owned, or controlled by, an ACCME-defined ineligible company. 

    The following individuals have indicated that they have not had, in the past 24 months, a relevant financial relationship(s) with ineligible companies to disclose:

    • Planners (Forefront Collaborative): Leah Johnson; Marianna Shershneva, MD, PhD

    The following individuals have disclosed that they have had a financial relationship in the past 24 months that has been deemed relevant to this activity. All relevant financial relationships have been mitigated:

    Faculty: Julie E. Chang, MD

    • Research Funding: Celgene, Genentech
    • Consultant: MorphoSys 
    • Advisory Board: BeiGene, Genentech
  • Target Audience

    This activity is designed to meet the educational needs of hematology/oncology specialists, as well as nurse practitioners, physician assistants, pharmacists, and other members of a healthcare team who are involved in treatment of patients with CLL or MCL.

  • Learning Objectives

    Upon completion of this activity, learners should increase their ability to:

    1. Describe the MOAs of covalent and non-covalent BTKi used to treat patients with certain B-cell malignancies.
    2. Examine the most frequent causes of treatment failure with standard, covalent BTKi seen in patients with relapsed/refractory CLL or MCL.
    3. Assess the efficacy and safety of novel, non-covalent BTKi advancing through clinical trials among patients with CLL and MCL.
    4. Discuss the potential role for non-covalent BTKi in the treatment algorithm for patients with relapsed/refractory CLL or MCL.
  • Accreditation and Credit Designation Statements

    Accreditation Statement
    Forefront Collaborative is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    Credit Designation Statement
    Forefront Collaborative designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

  • Disclaimer

    The views and opinions expressed in this activity are those of the faculty and do not necessarily reflect the views or recommendations of Forefront Collaborative and Lilly.

    The content of this activity was independently peer reviewed by two reviewers. The reviewers of this activity have no relevant financial relationships to disclose.

    This continuing medical education activity will include references to unlabeled or unapproved uses of drugs.

  • Provider(s)/Educational Partner(s)

    This activity is provided by Forefront Collaborative.

  • Commercial Support

    This activity is supported by an educational grant from Lilly.

  • System Requirements

    Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments

Schedule3 Mar 2024